Marvix AI
Marvix AI is built for specialty care rather than the short general outpatient visit most scribes assume, targeting long consults, complex histories and longitudinal care across neurology, oncology, orthopaedics and nephrology, with a claimed 135 or more specialties and subspecialties. It treats documentation as continuous rather than per encounter: pre charting pulls the schedule, prior notes, labs, imaging and medications before the visit, the encounter is captured or dictated, and context carries forward into composite notes and patient recaps. It names its personalisation technique, neural style transfer, to adapt phrasing to each clinician's existing documentation style, and it generates E/M levels, ICD-10 codes, modifiers and add on codes accompanied by explicit medical decision making rationale so a clinician can see why each was proposed. Integration is two way across a named list including athenahealth, Veradigm, AdvancedMD, eClinicalWorks, ModMed, DrChrono and NextGen. Its 30 day trial includes full features and full EHR integration, which the vendor rightly notes is unusual.
Capability Axes
Ambient capture, pre charting synthesis, note generation, letter production and coding are all model output, with no services layer or platform business underneath.
Notes and letters arrive chart ready for clinician review, and the coding path is more transparent than most: E/M levels, modifiers and add on codes are presented with the medical decision making rationale supporting them, so a clinician can see the basis for a suggestion rather than accepting a bare code. That is the traceability principle this index credits in Abridge and Lime Health, applied to coding. Held at B because no acceptance rate, edit burden figure or confidence threshold is published, and no explicit sign off gate is described.
Names its techniques rather than gesturing at them, which is uncommon at this size. Personalisation is attributed to NEURAL STYLE TRANSFER, a specific method rather than a claim that the system learns your style. Coding output carries explicit medical decision making rationale so the reasoning behind an E/M level is inspectable rather than asserted. Specialty behaviour is described concretely, including laterality propagation in orthopaedics, which is the kind of detail only a team that has worked the specialty would name. Held at B because no accuracy figure, model card or evaluation methodology was located.
No study, controlled evaluation, accuracy benchmark, third party rating, named customer or deployment count located. Note also that a substantial share of the comparison content ranking for competitor names in this category is published by Marvix itself, so search visibility here reflects content investment rather than market presence.
Not assessed. HIPAA compliance is claimed but no retention schedule for audio or transcripts, no de identification practice and no training use statement was located. The gap matters more than usual because pre charting ingests prior notes, labs, imaging and medications, so the product holds far more historical PHI than a capture only scribe.
HIPAA compliance stated consistently across product and store listings. Business associate agreement terms are not published for inspection.
Not assessed. No named or dated attestation and no trust centre located in this pass.
Not a regulated medical device and none claimed or required for ambient documentation.
On the coding gradient with a real counterweight. The gradient language is present, with marketing about improving E/M accuracy and capturing modifiers, and modifier and add on coding is where billing scrutiny concentrates. Against that, every code is delivered with explicit medical decision making rationale, which is the single most useful control on this axis because it converts a coding suggestion into an argument a clinician or auditor can evaluate rather than a number to accept. No fairness statement, subgroup analysis or accent and dialect disclosure was located, and no language coverage is claimed.
Named, broad and genuinely two way. Integrations are listed across athenahealth including Athena Flow and Athena Practice, Veradigm, AdvancedMD, eClinicalWorks, ModMed, DrChrono and NextGen, and the direction of travel is both ways: the product pulls patient history, prior notes, labs, imaging and medications to build the pre charting recap, then pushes structured notes, letters and codes back. Read access at that depth is a harder integration than note push and is what makes the longitudinal proposition work. Release notes show integrations being actively extended rather than listed once.
Not assessed. Cloud delivered with iOS and Android clients, but no hosting region, residency option or sub processor detail was located.
No rate card. Pricing is described as customised by practice size and specialty, which is a quote process. What is published and genuinely notable is the trial: 30 days with FULL feature access AND full bidirectional EHR integration included. Most trials in this category withhold the advanced workflow features that determine whether a product works in a specialty practice, and Marvix points that out itself. A trial that includes the integration is the closest thing to an honest evaluation a buyer can get without a contract.
Among the deepest specialty coverage in this index and specific about what depth means. A claimed 135 or more specialties and subspecialties, with named deep support for neurology, oncology, orthopaedics and nephrology, and capabilities that only matter inside those specialties: laterality propagation for orthopaedic documentation, oncology staging and treatment plan handling, and composite notes for patients whose history spans years rather than one visit. It also covers multi user workflows across medical assistants and providers with parallel rooming, vitals and pre charting, which reflects how specialty clinics actually run. Output extends to after visit summaries, referral letters and patient instructions.
Pricing
Vendor-published figures are labeled as such. Figures labeled “Estimated” are derived from third-party sources and have not been confirmed by the vendor.
| Entry Price | Pricing Basis | BAA Tier | Implementation | Source |
|---|---|---|---|---|
|
Not published. Quoted by practice size and specialty; 30 day full feature trial including EHR integration.
|
Not disclosed. Customised by practice size and specialty, sold to specialty practices, clinics and care teams. | HIPAA compliance stated. BAA terms not published. | None published. EHR integration is included in the trial rather than gated behind a paid tier. | Vendor Published |
No rate published; pricing is quoted by practice size and specialty. The 30 day trial is the substantive commercial disclosure here, because it includes full features and full bidirectional EHR integration rather than a stripped evaluation build, and integration behaviour is exactly what determines whether a specialty practice can use the product. Take the trial with the integration live and test the two things this product is actually built for: whether pre charting pulls the right history for a complex longitudinal patient, and whether the medical decision making rationale attached to each E/M code stands up to your own coder's reading.